

**Status of the claims:**

1. (Presently amended) A pharmaceutical composition comprising:
  - an effective amount of amlodipine;
  - an effective amount of hydroxylated atorvastatin metabolite (ATM); and
  - pharmaceutically acceptable formulation agents carrier or diluent,the ~~effect~~ effective amounts of amlodipine and ATM hydroxylated atorvastatin metabolite coordinated to substantially inhibit lipid peroxidation in human low density lipoprotein or lipid membrane to achieve a therapeutic effect.
2. (original)
3. (original)
4. (Presently amended) The pharmaceutical composition of claim 1 wherein said ~~pharmaceutical composition reduces~~ amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of reducing the risk of arterial and related heart disease.
5. (original)
6. (Presently amended) The pharmaceutical composition of claim 1 wherein said ~~pharmaceutical composition lowers~~ amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of lowering blood pressure.

7. (Presently amended) The pharmaceutical composition of claim 6 wherein the coordination is such that said pharmaceutical composition lowers blood pressure is lowered to a level consistent with a reduced risk of arterial and related heart disease.

8. (Presently amended) The pharmaceutical composition of claim 6 wherein the coordination is such that said pharmaceutical composition lowers blood pressure is lowered to a level statistically equivalent to normal.

9. (Presently amended) The pharmaceutical composition of claim 1 wherein the coordination is such that said pharmaceutical composition lowers systemic lipid concentrations are lowered.

10. (Presently amended) The pharmaceutical composition of claim 9 wherein said ~~pharmaceutical composition lowers~~ amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of lowering systemic lipid concentrations to a level consistent with a reduced risk of arterial and related heart disease.

11. (Presently amended) The pharmaceutical composition of claim 9 wherein said ~~pharmaceutical composition lowers~~ systemic lipid concentrations are lowered to a level statistically equivalent to normal.

12. (Presently amended) The pharmaceutical composition of claim 1 wherein said ~~pharmaceutical composition lowers~~ amounts of amlodipine and hydroxylated atorvastatin metabolite are coordinated to inhibit lipid peroxidation to the extent necessary to achieve the therapeutic effect of lowering blood pressure and systemic lipid concentrations.

13. (Presently amended) The pharmaceutical composition of claim 12 wherein said ~~pharmaceutical composition lowers~~ blood pressure and systemic lipid concentrations are lowered to a level consistent with a reduced risk of arterial and related heart disease.

14. (Presently amended) The pharmaceutical composition of claim 12 wherein said ~~pharmaceutical composition lowers~~ blood pressure and systemic lipid concentrations are lowered to a level statistically equivalent to normal.

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Presently amended) A pharmaceutical composition comprising:

a therapeutically effective amount of a combination of amlodipine and hydroxylated atorvastatin metabolite; and

pharmaceutically acceptable ~~formulation agents~~ carriers or diluents

wherein said pharmaceutical composition lowers blood pressure and systemic lipid concentrations at least partially as a result of reduced lipid oxidation.

25. (Presently amended) The pharmaceutical composition of claim 22 wherein said ~~pharmaceutical composition reduces~~ therapeutically effective amount is selected such that the risk of arterial and related heart disease is reduced.

26. (Original)

27. (Presently amended) The pharmaceutical composition of claim 22 wherein said ~~pharmaceutical composition lowers~~ therapeutically effective amount is selected such that blood pressure and systemic lipid concentrations are lowered to a level consistent with a reduced risk of arterial and related heart disease.

28. (Presently amended) The pharmaceutical composition of claim 22 wherein said ~~pharmaceutical composition lowers~~ therapeutically effective amount is selected such that blood pressure and systemic lipid concentrations are lowered to a level statistically equivalent to normal.

Claims 29-56 are withdrawn due to restriction requirement.

57. (Presently amended) A pharmaceutical composition comprising:
- an amount of amlodipine;
  - an amount of hydroxylated atorvastatin metabolite; and
  - pharmaceutically effective ~~formulation agents~~ carriers or diluents.

Claims 60-62 are withdrawn due to restriction requirement.

63. (New) A pharmaceutical composition comprising:
- an amount of amlodipine;
  - an amount of hydroxylated atorvastatin metabolite; and
  - a pharmaceutically acceptable carrier or diluent;
- wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that an antioxidant effect is achieved by the combined amounts which is greater than the antioxidant effect of either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.

64. (New) A pharmaceutical composition comprising:
- an amount of amlodipine;
  - an amount of hydroxylated atorvastatin metabolite; and
  - a pharmaceutically acceptable carrier or diluent;
- wherein said amounts of amlodipine and hydroxylated atorvastatin metabolite are selected such that the inhibition of lipid peroxidation achieved by the combined amounts is greater than the inhibition of lipid peroxidation achieved by either said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite separately.

65. (New) The pharmaceutical composition of claim 64 wherein said selection is further coordinated for achieving an antioxidant effect, which effect is greater than the antioxidant effect achieved by said amount of amlodipine or said amount of hydroxylated atorvastatin metabolite independently.